BEIJING, Dec. 31, 2010 /PRNewswire-Asia/ — Sinovac Biotech Ltd.
(Nasdaq:
SVA), a leading provider of biopharmaceutical products in
China, announced today its common shares will be listed on the
NASDAQ Global Select Market effective January 3, 2011. The
Company received notification from the NASDAQ Stock Market dated
December 7, 2010 that as part of the exchange’s annual review of
Global Market issuers it has met the initial listing requirements
of the Global Select Market and is eligible for inclusion.
Sinovac’s common shares commenced trading on the NASDAQ Global
Market on November 16, 2009.
Dr. Weidong Yin, Chairman, President & CEO, stated, “We look
forward to trading on the Global Select Market in January 2011 as
we have met the high listing standards of this market tier.
We are focused on advancing our development pipeline and
commercializing our high quality vaccines as we build shareholder
value as a leading China-based biopharmaceutical company.”
AboutSinovacSinovac Biotech Ltd. is a China-based
biopharmaceutical company that focuses on the research,
development, manufacture and commercialization of vaccines that
protect against human infectious diseases including hepatitis A,
seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1
influenza. In 2009, Sinovac was the first company worldwide to
receive approval for its H1N1 influenza vaccine, PANFLU.1, and has
received orders from the Chinese Central Government pursuant to the
government stockpiling program. The Company is developing a number
of new vaccine products, including vaccines for pneumococcal
conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth
Disease), Japanese Encephalitis, animal and human rabies, HIB and
epidemic meningitis, chickenpox, mumps and rubella. Its wholly
owned subsidiary, Tangshan Yian, is focusing on the research,
development, manufacturing and c
‘/>”/>
SOURCE
